soul trial oral semaglutide cardiovascular outcomes trial (Semaglutide triaL) in individuals with Cardiovascular Outcomes, Safety, and Tolerability

James Januzzi, MD Although our primary endpoint fell short of statistical significance, there are encouraging signals in these results that increase enthusiasm to further evaluate effects of AT-001 on diabetic cardiomyopathy, saidJames Januzzi, MD, Hutter Family Professor of Medicine atHarvard Medical School, a cardiologist atMassachusetts General Hospital, director of Heart Failure Trials at theBaim Institute for Clinical Researchand the studys lead author

Janet Klein, MS RDN, CDN, CDCES, Bariatric Surgery and Obesity Medicine Program Director

Johnson & Johnsons Darzalex remained a standout performer in oncology

Learn the realistic timeline, what to expect from your treatment, and tips to maximize resultsincluding DISONCARE products that support your health journey.